A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
Latest Information Update: 10 Jun 2024
Price :
$35 *
At a glance
- Drugs Respiratory syncytial virus vaccine adjuvanted (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacodynamics; Registrational
- Acronyms AReSVi 004; RSV OA-ADJ-004
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 20 Dec 2023 Planned End Date changed from 24 May 2024 to 25 May 2026.
- 14 Dec 2023 Interim Results on humoral and cell-mediated immunogenicity, reactogenicity, and safety until one year post-dose 1, published in the Journal of Infectious Diseases
- 19 Oct 2021 Planned End Date changed from 21 May 2024 to 24 May 2024.